Drugs / LY3537021
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT05444569 | Aug 2022 → Feb 2023 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT04586907 | Nov 2020 → Nov 2021 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07169851 | Nov 2025 → Dec 2026 expected | neoplasm | Eli Lilly and Company | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LY3537021 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05444569 ↗ |
| Action | Activate | “long-acting GIPR agonist LY3537021” PMID 41391569 ↗ Dec 2025 |
| Route | Subcutaneous | “There was no delay in gastric emptying following a single subcutaneous dose of 0.3-25 mg LY3537021.” PMID 41391569 ↗ Dec 2025 |
| Target | GIPR | “In vitro, LY3537021 demonstrated potency greater than native GIP and selectivity for the GIPR.” PMID 41391569 ↗ Dec 2025 |